Estimaciones de analistas de Wall Street para BioCryst Pharmaceuticals, Inc. (BCRX): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-02 | $0.10 | ||
| 2026-08-05 | $0.30 | $0.15 | +94.6% |
| 2026-05-06 | $-2.98 | $0.06 | -5066.7% |
| 2026-02-26 | $1.12 | $0.07 | +1500.0% |
| 2025-11-03 | $0.06 | $0.07 | -14.3% |
| 2025-08-04 | $0.02 | $0.03 | -33.3% |
| 2025-05-05 | $0.00 | $-0.07 | +100.2% |
| 2025-02-24 | $-0.13 | $-0.07 | -85.7% |
Ratios de valoración
| Precio / Valor contable | -4.79 |
| EV / EBITDA | -7.75 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $26.4M | $25.2M | $20.7M | $48.8M | $17.8M | $157.2M | $270.8M | $331.4M | $450.7M | $874.8M |
| Coste de Ventas | $2.7M | $1.7M | $471000 | $4.1M | $1.7M | $7.3M | $6.6M | $4.7M | $12.5M | $19.1M |
| Beneficio Bruto | $23.7M | $23.5M | $20.2M | $44.7M | $16.1M | $149.9M | $264.2M | $326.8M | $438.2M | $855.8M |
| I+D | $61.0M | $67.0M | $84.9M | $107.1M | $123.0M | $208.8M | $253.3M | $216.6M | $174.6M | $166.1M |
| Generales y Administrativos | $11.3M | $13.9M | $29.5M | $37.1M | $67.9M | $118.8M | $159.4M | $213.9M | $266.1M | $348.6M |
| Gastos Operativos | $72.3M | $80.9M | $114.4M | $144.2M | $190.9M | $327.6M | $412.7M | $430.5M | $440.8M | $514.8M |
| Beneficio Operativo | -$48.6M | -$57.4M | -$94.2M | -$99.5M | -$174.8M | -$177.7M | -$148.4M | -$103.7M | -$2.5M | $341.0M |
| EBITDA | -$48.2M | -$56.5M | -$90.4M | -$96.3M | -$167.6M | -$121.7M | -$143.9M | -$116.3M | $12.8M | $347.7M |
| Gastos por Intereses | $6.5M | $8.6M | $9.2M | $11.9M | $14.5M | $59.3M | $99.1M | $108.2M | $98.5M | $78.9M |
| Beneficio Antes de Impuestos | -$55.1M | -$65.8M | -$101.3M | -$108.9M | -$182.8M | -$181.8M | -$244.4M | -$226.2M | -$87.0M | $267.4M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | $2.3M | $2.7M | $310000 | $1.9M | $3.5M |
| Beneficio Neto | -$55.1M | -$65.8M | -$101.3M | -$108.9M | -$182.8M | -$184.1M | -$247.1M | -$226.5M | -$88.9M | $263.9M |
| BPA | $-0.75 | $-0.78 | $-0.98 | $-0.94 | $-1.09 | $-1.03 | $-1.33 | $-1.18 | $-0.43 | $1.26 |
| BPA Diluido | $-0.75 | $-0.78 | $-0.98 | $-0.94 | $-1.09 | $-1.03 | $-1.33 | $-1.18 | $-0.43 | $1.21 |
| Acciones en Circulación (Diluidas) | $73.7M | $84.5M | $103.2M | $115.6M | $167.3M | $179.1M | $185.9M | $192.2M | $206.7M | $218.6M |
Precio
| Precio | $8.43 |
| Capitalización | $2.1B |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: ARDX · MAZE · NTLA · PHVS · STOK · SYRE · TRVI
Explorar sector: Healthcare · Biotechnology
Más secciones de BCRX: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones